DEPARTMENT OF PSYCHIATRY GRAND ROUNDS NOTICE

WEDNESDAY, 1:00 - 2:30 P.M., Lecture Hall 1, BSB

April 3, 2013 – April 24, 2013

Target Audience: Psychiatric physicians, residents, psychologists, nurse practitioners, social workers, occupational and recreational therapists, medical students, trainees and those who provide services to the mentally ill.

April 3, 2013  Michael Flaum, MD
Clinical Professor of Psychiatry
University of Iowa Carver College of Medicine
(Disclosure: None)

Topic: Motivational Interviewing as a Foundation for Recovery Oriented Practice

Learning Objectives: At the conclusion of this presentation, participants should be able to:
1) Explain what is meant by the “paradoxical effect of coercion”
2) Identify and describe at least 3 components of the “spirit” of motivational interviewing
3) Discuss at least 2 ways in which the spirit of motivational interviewing is consistent with fundamental components of mental health recovery

Dr. HENRI BEGLEITER MEMORIAL GRAND ROUNDS

April 10, 2013  John H. Krystal, M.D.
Chair, Department of Psychiatry
Yale University School of Medicine
Chief of Psychiatry Services, Yale-New Haven Hospital
(Disclosure: See Attached)

Topic: Glutamate and the Vulnerability to Alcoholism: An update on the Past Decade of Research

Learning Objectives: 1) To describe the role of glutamate receptor dysregulation in alcohol reward, alcohol dependence, and the vulnerability to alcoholism.
2) To describe alterations in neural circuits related to the vulnerability to alcoholism and to relate these alterations to interplay of glutamate and dopamine.
3) To introduce the phases of reward-related learning: classical conditioning, Pavlovian-to-Instrumental Transfer, and Habit.
4) To describe distinct patterns of medication effects on different aspects of drinking (craving, consumption).
April 17, 2013  Jeffrey Lieberman, MD
President Elect, American Psychiatric Association
(Disclosure – )

Topic:

Learning Objectives: 1)

---

April 24, 2013  Dev Devanand, MD
Professor of Clinical Psychiatry and Neurology
College of Physicians and Surgeons, Columbia University
(Disclosure – Eli Lilly research support not related to this talk.)

Topic: Psychopathology and its Treatment in Alzheimer's Disease

Learning Objectives: 1) Recognize the prevalence of different types of psychiatric symptoms in patients with Alzheimer's disease.
2) Evaluate the relative merits of low dose antipsychotic use to treat psychosis and agitation in Alzheimer's disease

Off Label Drugs Device Usage: (Session on 4/24/13) - All medications discussed to treat psychosis and agitation in Alzheimer's disease are off-label because the FDA has not approved any medication for this purpose. This will also be indicated in the talk.

Accreditation Statement:
The State University of New York (SUNY) Downstate Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
SUNY Downstate Medical Center designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement
SUNY Downstate Medical Center Office of CME (OCME) and its affiliates are committed to providing educational activities that are objective, balanced and as free of bias as possible. The OCME has established policies that will identify and resolve all conflicts of interest prior to this educational activity. All participating faculty are expected to disclose to the audience, verbally or in writing, any commercial relationships that might be perceived as a real or apparent conflict of interest related to the content of their presentations, and unlabeled/unapproved uses of drugs and devices. Detailed disclosures will be made verbally and/or in writing during the program.
John H. Krystal, MD

2013 Financial Disclosure

Consultant
Note: – The Individual Consultant Agreements listed below are less than $10,000 per year
AbbVie, Inc. (formerly Abbott Laboratories)
AMGEN
AstraZeneca Pharmaceuticals
Bristol-Myers Squibb
Eli Lilly and Co.
Lundbeck Research USA
Biomedisyn Corporation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sage Therapeutics, Inc.
Shire Pharmaceuticals
Sunovion Pharmaceuticals, Inc.
Takeda Industries
Teva Pharmaceutical Industries, Ltd.

Scientific Advisory Board
CHDI Foundation, Inc.
Lohocla Research Corporation
Mnemosyne Pharmaceuticals, Inc.
Naurex, Inc.
Pfizer Pharmaceuticals

Board of Directors:
Coalition for Translational Research in Alcohol and Substance Use Disorders

President:
American College of Neuropsychopharmacology

Income Greater than $10,000
Editorial Board
Editor - Biological Psychiatry

Employment:
Yale University School of Medicine
VA CT Healthcare System

Patents and Inventions
2) Vladimir, Coric, Krystal, John H, Sanacora, Gerard – Glutamate Agents in the Treatment of Mental Disorders No 11/399,188 April 5, 2006 (Pending).
3) Intranasal Administration of Ketamine to Treat Depression (Pending)